Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrafy Life SciencesASX:VFY -1.53%4 EV-to-EBIT is -15.72 as of Sep. 06, 2026. GuruFocus rates ASX:VFY with a GF Score™ of 4/100. The stock has 2 warning signs investors should review. Among 1,764 Software companies, Vitrafy Life Sciences ranks worse than 56689.29% on this metric.
Vitrafy Life Sciences (ASX:VFY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vitrafy Life Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was A$186.05 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vitrafy Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was A$-16.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VFY vs MSFT, PLTR, ORCL: EV-to-EBIT Comparison
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences EV-to-EBIT vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's EV-to-EBIT falls into.
Vitrafy Life Sciences's current Enterprise Value is A$254.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vitrafy Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was A$-16.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrafy Life Sciences (ASX:VFY) has a EV-to-EBIT of -15.72 as of Sep. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vitrafy Life Sciences and its competitors. According to the industry distribution chart, Vitrafy Life Sciences ranks #999999 out of 1764 companies in the Software industry.
Is Vitrafy Life Sciences' EV-to-EBIT too high?
Vitrafy Life Sciences' current EV-to-EBIT is -15.72. Based on the distribution chart, Vitrafy Life Sciences ranks #999999 out of 1764 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' EV-to-EBIT compare to MSFT and PLTR?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #999999 out of 1764 companies for EV-to-EBIT. This places Vitrafy Life Sciences in the lower half of its industry. The industry median EV-to-EBIT is 13.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Software company?
The median EV-to-EBIT among Software companies is 13.89, based on 1,764 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median EV-to-EBIT is 13.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current EV-to-EBIT is -15.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current EV-to-EBIT of -15.72. The current EV-to-EBIT is -15.72. Vitrafy Life Sciences' overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current EV-to-EBIT is -15.72 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
4GF Score
Get the complete analysis for ASX:VFY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
